Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Schedule of deferred revenue

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's IO Collaboration with Sanofi:

	As of December 31,
	2018		2017
Accounts receivable	$	77.9	$	59.3
Deferred revenue	$	289.9	$	440.0

Significant changes in deferred revenue balances are as follows:

	Year Ended December 31, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	93.6
Net decrease as a result of cumulative catch-up adjustments arising from changes in the estimate of the stage of completion	$	(135.0	)
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(108.7	)

The following tables summarize accounts receivable and deferred revenue information in connection with the Teva Collaboration Agreement:

	As of December 31,
	2018		2017
Accounts receivable (recorded within Prepaid expenses and other current assets)	$	28.8	$	71.3
Deferred revenue	$	194.5	$	197.4

Significant changes in deferred revenue balances are as follows:

	Year Ended December 31, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	48.2
Increase due to amounts invoiced, excluding amounts recognized as revenue during the period	$	30.7
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(83.8	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's Antibody Collaboration with Sanofi:

	As of December 31,
	2018		2017
Accounts receivable	$	138.2	$	121.0
Deferred revenue	$	236.1	$	117.7

Significant changes in deferred revenue balances are as follows:

	Year Ended December 31, 2018
Increase due to shipments of commercial supplies to Sanofi	$	251.6
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(133.2	)

Deferred revenue consists of the following:

	As of December 31,
	2018		2017
Current portion:
Received or receivable from Sanofi (see Note 3a)	$	246.7	$	177.7
Received or receivable from Bayer (see Note 3b)	44.4		39.0
Received or receivable from Teva (see Note 3c)	92.5		43.5
Other	68.9		59.9
	$	452.5	$	320.1
Long-term portion:
Received or receivable from Sanofi (see Note 3a)	$	279.3	$	379.9
Received or receivable from Bayer (see Note 3b)	45.1		29.7
Received or receivable from Teva (see Note 3c)	102.0		153.9
Other	37.8		65.7
	$	464.2	$	629.2